MedTrace Logo

Mobile Health Device Study for Myeloma Patients

NCT03006315 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-11-19

No results posted yet for this study

Summary

Enrolled participants health status will be tracked by using a mobile health-monitoring device while undergoing chemotherapy for multiple myeloma.

Conditions

Interventions

DEVICE

Garmin Vivofit device

Participants will be bio-monitored using the Garmin Vivofit mobile wearable device at baseline (at least 1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT.

BEHAVIORAL

Mobile Health quality of life assessements

Sponsors & Collaborators

Principal Investigators

  • Neha Korde, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2024-11-14
Completion
2024-11-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03006315 on ClinicalTrials.gov